

Female (n=4692)




Male (n=5974)




Propensity score matching + adjust

Female (n=4692)




Male (n=5974)




Adjust

Female (n=11356)





Male (n=17329)





■ SGLT2 ■ GLP1







■ SGLT2 ■ GLP1

Propensity score matching + adjusted

SGLT2 GLP1

■ SGLT2 ■ GLP1







Adjusted

■ SGLT2 ■ GLP1


■ SGLT2 ■ GLP1

Male (n=25268)





Predicted weight change (kg)



-2

Predicted eGFR change

-2

Predicted eGFR change




■ SGLT2 ■ GLP1

SGL12 GLP


Female (n=13711) Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=971, event = 167)
3-5 mmol/mol (n=790, event = 128)
0-3 mmol/mol (n=3078, event = 547)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=4383, event = 845)
3-5 mmol/mol (n=2600, event = 509)
>5 mmol/mol (n=1889, event = 450)



Male (n=17281)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2072, event = 292)
3–5 mmol/mol (n=2805, event = 434)
0–3 mmol/mol (n=6467, event = 1001)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=4289, event = 711)
3–5 mmol/mol (n=977, event = 180)
>5 mmol/mol (n=671, event = 151)
Average treatment effect



■ SGLT2 ■ GLP1

■ SGLT2 ■ GLP1


■ SGLT2 ■ GLP1

Propensity score matching + adjusted

■ SGLT2 ■ GLP1

Male (n=17281)


Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=2072, event = 292) 3–5 mmol/mol (n=2805, event = 434) 0–3 mmol/mol (n=6467, event = 1001) Predicted HbA1c benefit on GLP1–RA 0–3 mmol/mol (n=4289, event = 711) 3–5 mmol/mol (n=977, event = 180) >5 mmol/mol (n=671, event = 151) Average treatment effect



Female (n=13711)

Average treatment effect

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=971, event = 167) 3–5 mmol/mol (n=790, event = 128) 0–3 mmol/mol (n=3078, event = 547) Predicted HbA1c benefit on GLP1–RA 0–3 mmol/mol (n=4383, event = 845) 3–5 mmol/mol (n=2600, event = 509) >5 mmol/mol (n=1889, event = 450) Average treatment effect



Adiusted

■ SGLT2 ■ GLP1


1-1- (-- 400E4)

Male (n=46354)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=4277, event = 563)
3-5 mmol/mol (n=6164, event = 861)
0-3 mmol/mol (n=17011, event = 2638)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=13964, event = 2287)
3-5 mmol/mol (n=3109, event = 573)
>5 mmol/mol (n=1829, event = 389)

Average treatment effect



10 15 20 25 30 35 40

Discontinuation (%)

45 50

Female (n=31387)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1771, event = 288)
3–5 mmol/mol (n=1493, event = 231)
0–3 mmol/mol (n=6235, event = 1115)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=10295, event = 2005)
3–5 mmol/mol (n=7059, event = 1401)
>5 mmol/mol (n=4534, event = 1072)

Average treatment effect


0 5 10 15 20 25 30 35 40 45 50

Discontinuation (%)

Female (n=8235)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=644, event = 11) 3–5 mmol/mol (n=491, event = 6) 0–3 mmol/mol (n=1975, event = 34) Predicted HbA1c benefit on GLP1–RA 0–3 mmol/mol (n=2570, event = 57) 3–5 mmol/mol (n=1749, event = 42) >5 mmol/mol (n=806, event = 31) Average treatment effect 0.25 0.50 1.0 2.0 4.0


Male (n=8859)




Propensity score matching + adjusted

Hazards ratio

Female (n=8235)




Male (n=8859)




Adjusted


Female (n=22122)




Male (n=29930)



Female (n=8235)




Male (n=8859)




Hazards ratio

Propensity score matching + adjusted

Female (n=8235)




Male (n=8859)




Adjusted

Female (n=22122)



Male (n=29930)




Female (n=9095)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=658, event = 5)
3-5 mmol/mol (n=522, event = 1)
0-3 mmol/mol (n=1982, event = 13)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2786, event = 24)
3-5 mmol/mol (n=1922, event = 16)
>5 mmol/mol (n=1225, event = 25)

Male (n=9459)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1216, event = 16)
3-5 mmol/mol (n=1580, event = 12)
0-3 mmol/mol (n=3582, event = 48)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2368, event = 44)
3-5 mmol/mol (n=425, event = 8)
>5 mmol/mol (n=288, event = 7)



Propensity score matching + adjusted

0.25

0.50

1.0

Hazards ratio

2.0

4.0

Female (n=9095)

Average treatment effect

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=658, event = 5)
3-5 mmol/mol (n=522, event = 1)
0-3 mmol/mol (n=1982, event = 13)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2786, event = 24)
3-5 mmol/mol (n=1922, event = 16)
>5 mmol/mol (n=1225, event = 25)

Average treatment effect


0.062 0.125 0.250 0.500 1.00 2.00 4.00

Hazards ratio

Male (n=9459)

Average treatment effect

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1216, event = 16)
3-5 mmol/mol (n=1580, event = 12)
0-3 mmol/mol (n=3582, event = 48)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2368, event = 44)
3-5 mmol/mol (n=425, event = 8)
>5 mmol/mol (n=288, event = 7)
Average treatment effect



Adjusted

Female (n=23621)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1329, event = 11)
3-5 mmol/mol (n=1129, event = 2)
0-3 mmol/mol (n=4651, event = 27)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=7622, event = 71)
3-5 mmol/mol (n=5715, event = 46)
>5 mmol/mol (n=3175, event = 51)

Average treatment effect

0.50

1.0

2.0


4.0

8.0

Hazards ratio

Male (n=31231)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2991, event = 32)
3-5 mmol/mol (n=4277, event = 39)
0-3 mmol/mol (n=11983, event = 146)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=9520, event = 127)
3-5 mmol/mol (n=1533, event = 33)
>5 mmol/mol (n=927, event = 20)
Average treatment effect



Female (n=10585)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=715, event = 3)
3–5 mmol/mol (n=578, event = 2)
0–3 mmol/mol (n=2265, event = 5)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=3249, event = 17)
3–5 mmol/mol (n=2267, event = 12)
>5 mmol/mol (n=1511, event = 16)

Average treatment effect

0.12 0.25 0.50 1.0 2.0

Male (n=12257)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1359, event = 4)
3–5 mmol/mol (n=1880, event = 8)
0–3 mmol/mol (n=4468, event = 32)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=3275, event = 20)
3–5 mmol/mol (n=754, event = 10)
>5 mmol/mol (n=521, event = 15)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Hazards ratio

Propensity score matching + adjusted

Hazards ratio

Hazards ratio

Female (n=10585)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=715, event = 3)
3–5 mmol/mol (n=578, event = 2)
0–3 mmol/mol (n=2265, event = 5)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=3249, event = 17)
3–5 mmol/mol (n=2267, event = 12)
>5 mmol/mol (n=1511, event = 16)

Average treatment effect

0.12 0.25 0.50 1.0 2.0 4.0

Male (n=12257)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=1359, event = 4) 3-5 mmol/mol (n=1880, event = 8)0-3 mmol/mol (n=4468, event = 32)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=3275, event = 20)3-5 mmol/mol (n=754, event = 10)>5 mmol/mol (n=521, event = 15) Average treatment effect 0.12 0.25 0.50 2.0 1.0 4.0 Hazards ratio

Adjusted

Female (n=27172)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1427, event = 3)
3–5 mmol/mol (n=1240, event = 2)
0–3 mmol/mol (n=5185, event = 9)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=8812, event = 28)
3–5 mmol/mol (n=6589, event = 22)
>5 mmol/mol (n=3919, event = 37)

Average treatment effect

0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0 2.83

Hazards ratio

Male (n=39256)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=3338, event = 8)
3–5 mmol/mol (n=4948, event = 15)
0–3 mmol/mol (n=14228, event = 53)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=12515, event = 53)
3–5 mmol/mol (n=2630, event = 23)
>5 mmol/mol (n=1597, event = 26)

Average treatment effect

0.25
0.50
1.0
2.0
Hazards ratio